265 related articles for article (PubMed ID: 25155934)
1. Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy.
Ma CL; Wu XY; Zheng J; Wu ZY; Hong Z; Zhong MK
Pharmacogenomics; 2014 Jul; 15(10):1323-36. PubMed ID: 25155934
[TBL] [Abstract][Full Text] [Related]
2. SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy.
Ma CL; Wu XY; Jiao Z; Hong Z; Wu ZY; Zhong MK
Pharmacogenomics; 2015; 16(4):347-60. PubMed ID: 25823783
[TBL] [Abstract][Full Text] [Related]
3. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization.
Hung CC; Chang WL; Ho JL; Tai JJ; Hsieh TJ; Huang HC; Hsieh YW; Liou HH
Pharmacogenomics; 2012 Jan; 13(2):159-69. PubMed ID: 22188362
[TBL] [Abstract][Full Text] [Related]
4. SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis.
Haerian BS; Baum L; Kwan P; Tan HJ; Raymond AA; Mohamed Z
Pharmacogenomics; 2013 Jul; 14(10):1153-66. PubMed ID: 23859570
[TBL] [Abstract][Full Text] [Related]
5. SCN1AIVS5-91G>A polymorphism is associated with susceptibility to epilepsy but not with drug responsiveness.
Kumari R; Lakhan R; Kumar S; Garg RK; Misra UK; Kalita J; Mittal B
Biochimie; 2013 Jun; 95(6):1350-3. PubMed ID: 23466530
[TBL] [Abstract][Full Text] [Related]
6. SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients.
Shi L; Zhu M; Li H; Wen Z; Chen X; Luo J; Lin C; Zhang Z
Eur J Clin Pharmacol; 2019 May; 75(5):655-663. PubMed ID: 30693367
[TBL] [Abstract][Full Text] [Related]
7. Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy.
Ma CL; Jiao Z; Wu XY; Hong Z; Wu ZY; Zhong MK
Pharmacogenomics; 2015; 16(13):1499-512. PubMed ID: 26314341
[TBL] [Abstract][Full Text] [Related]
8. Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: Associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms.
Yang X; Yan Y; Fang S; Zeng S; Ma H; Qian L; Chen X; Wei J; Gong Z; Xu Z
Medicine (Baltimore); 2019 Mar; 98(12):e14908. PubMed ID: 30896644
[TBL] [Abstract][Full Text] [Related]
9. Association of SCN1A, SCN2A, and UGT2B7 Polymorphisms with Responsiveness to Valproic Acid in the Treatment of Epilepsy.
Lu Y; Su Q; Li M; Dayimu A; Dai X; Wang Z; Che F; Xue F
Biomed Res Int; 2020; 2020():8096235. PubMed ID: 32185219
[TBL] [Abstract][Full Text] [Related]
10. Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients.
Daci A; Beretta G; Vllasaliu D; Shala A; Govori V; Norata GD; Krasniqi S
PLoS One; 2015; 10(11):e0142408. PubMed ID: 26555147
[TBL] [Abstract][Full Text] [Related]
11. ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients.
Qu J; Zhou BT; Yin JY; Xu XJ; Zhao YC; Lei GH; Tang Q; Zhou HH; Liu ZQ
CNS Neurosci Ther; 2012 Aug; 18(8):647-51. PubMed ID: 22630058
[TBL] [Abstract][Full Text] [Related]
12. Effects of SCN1A and SCN2A polymorphisms on responsiveness to valproic acid monotherapy in epileptic children.
Liu M; Mao J; Xu H; Wang J; Zhao P; Xu Q; Du Z
Epilepsy Res; 2020 Dec; 168():106485. PubMed ID: 33096315
[TBL] [Abstract][Full Text] [Related]
13. Association between SCN1A polymorphism and carbamazepine responsiveness in epilepsy: A meta-analysis.
Zhang X; Liu J; Ye J
Epilepsy Res; 2021 Oct; 176():106627. PubMed ID: 34218210
[TBL] [Abstract][Full Text] [Related]
14. Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy.
Yun W; Zhang F; Hu C; Luo X; Xue P; Wang J; Ge Y; Meng H; Guo Y
Epilepsy Res; 2013 Dec; 107(3):231-7. PubMed ID: 24125961
[TBL] [Abstract][Full Text] [Related]
15. Associations between CYP3A4, CYP3A5 and SCN1A polymorphisms and carbamazepine metabolism in epilepsy: A meta-analysis.
Zhao GX; Zhang Z; Cai WK; Shen ML; Wang P; He GH
Epilepsy Res; 2021 Jul; 173():106615. PubMed ID: 33756436
[TBL] [Abstract][Full Text] [Related]
16. Effects of SCN1A and SCN2A polymorphisms on responsiveness to valproic acid monotherapy in epileptic children: A protocol for systematic review and meta-analysis.
Wen Z; Chen J; Zhu B; Lu Y; Chen L
Medicine (Baltimore); 2021 May; 100(20):e25831. PubMed ID: 34011048
[TBL] [Abstract][Full Text] [Related]
17. Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy.
Ufer M; von Stülpnagel C; Muhle H; Haenisch S; Remmler C; Majed A; Plischke H; Stephani U; Kluger G; Cascorbi I
Pharmacogenet Genomics; 2011 Oct; 21(10):624-30. PubMed ID: 21799461
[TBL] [Abstract][Full Text] [Related]
18. Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy.
He XJ; Jian LY; He XL; Tang M; Wu Y; Xu YY; Sun XJ; Zhao LM
Epilepsia; 2014 Aug; 55(8):1301-6. PubMed ID: 24861996
[TBL] [Abstract][Full Text] [Related]
19. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy.
Abe T; Seo T; Ishitsu T; Nakagawa T; Hori M; Nakagawa K
Br J Clin Pharmacol; 2008 Aug; 66(2):304-7. PubMed ID: 18489610
[TBL] [Abstract][Full Text] [Related]
20. Association between SCN1A gene polymorphisms and drug resistant epilepsy in pediatric patients.
Margari L; Legrottaglie AR; Vincenti A; Coppola G; Operto FF; Buttiglione M; Cassano A; Bartolomeo N; Mariggiò MA
Seizure; 2018 Feb; 55():30-35. PubMed ID: 29353705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
